Amid a global landscape fraught with uncertainty—driven by ongoing Middle East tensions and their ripple effects on international trade—the Ministry of Pharmaceutical Industry has acted decisively. It issued an urgent directive to all entities involved in manufacturing, importing, and distributing pharmaceutical products, aiming to head off potential disruptions to medicine supplies.
The ministry’s notice opens by warning that current geopolitical shifts could “disrupt global supply chains, particularly for raw pharmaceutical materials, intermediate goods, and finished medications.” Without strict oversight, this could threaten “the steady availability of products on the domestic market in the coming weeks or months.”
To counter these threats, the ministry has raised the alert level. Companies must now conduct “daily, meticulous, and recorded monitoring of their supply schedules, whether for imports or domestic production.” This applies across the entire pipeline, from ordering inputs to delivering final products.
Any emerging issues must be reported immediately to the relevant authorities. The ministry stressed the need for “complete transparency” and “swift responsiveness” to enable quick risk assessments and, if needed, tailored corrective actions.
A dedicated communication channel has been activated for this purpose. Firms are required to report constraints via the email: [email protected]. This setup centralizes data, streamlines information flow, and ensures prompt handling of critical situations.
Safeguarding Public Health
The directive also serves as a firm reminder of legal duties governing pharmaceutical operations. It highlights amendments in Article 162 of Finance Law No. 25-17, dated December 14, 2025—which updates and bolsters provisions from Article 61 of Finance Law No. 22-24, dated December 25, 2022.
Key requirements include mandatory, regular reporting of pharmaceutical stockpiles through the ministry’s digital platform. This provides real-time national visibility into availability, essential for spotting pressures on specific drugs or treatment categories.
Operators must also strictly adhere to pre-approved production and import plans. Any failure to meet these—due to external or internal factors—requires instant notification. The ministry noted that violations could trigger penalties under current laws, ranging from administrative measures to harsher enforcement based on severity.
Through this forward-thinking approach, Algerian authorities are signaling their commitment to averting any domestic supply gaps amid volatile world conditions. The stakes go beyond economics: they involve ensuring uninterrupted treatment access for patients and upholding national health security.
This effort aligns with broader goals to bolster the pharmaceutical system’s resilience, including boosting local manufacturing, diversifying suppliers, and enhancing monitoring tools.
In closing, the Ministry of Pharmaceutical Industry emphasized the directive’s binding nature and urged full compliance from all operators. In an unpredictable global setting, discipline, openness, and quick action are vital to maintaining market stability and medicine access.